<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169195</url>
  </required_header>
  <id_info>
    <org_study_id>R-GEMOX</org_study_id>
    <nct_id>NCT00169195</nct_id>
  </id_info>
  <brief_title>Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma</brief_title>
  <official_title>Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in
      refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible
      for autologous transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, open-label, non-randomized clinical study, evaluating the efficacy
      and the safety of R-GEMOX in refractory/relapsed patients aged from 18 to 75 years with
      CD20-positive large B-cell lymphoma non eligible for autologous transplantation.

      It is anticipated that 50 subjects will be enrolled over 4 years (from April 2003/January
      2007), but inclusion could stop earlier according to the analysis performed every 5 patients
      (based on triangular test).

      The duration of the treatment period is approximately 16 weeks and patients are followed
      until death.

      The total duration of the study is expected to be 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) (complete response, [CR]; unconfirmed complete response, [CRu] and partial response, [PR])</measure>
    <time_frame>8 weeks</time_frame>
    <description>4 cycles of R-GEMOX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) (complete response, [CR]; unconfirmed complete response, [CRu] and partial response, [PR])</measure>
    <time_frame>16 weeks</time_frame>
    <description>completion of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-GEMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)</intervention_name>
    <arm_group_label>R-GEMOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with histologically or cytologically proven, CD 20+, diffuse large
             B-cell lymphoma,

          -  Relapse after first or second CR, PR or less than PR to first-line treatment for the
             rituximab-naïve patients, OR relapse after first or second CR with a minimum delay of
             12 months between the last rituximab infusion and the inclusion for the
             rituximab-experienced patients

          -  Aged 18 - 75 years

          -  Not eligible for autologous transplantation

          -  Previously treated with chemotherapy containing anthracycline, with or without
             rituximab

          -  ECOG performance status 0 to 2

          -  With a minimum life expectancy of 3 months

          -  Having signed informed consent form prior to enrollment

        Exclusion Criteria:

          -  Burkitt's, mantle cell, T-cell lymphomas

          -  CD 20-negative lymphoma

          -  HIV or HBV related disease

          -  Central nervous system or meningeal involvement by the lymphoma

          -  Not previously treated with anthracycline-containing regimens

          -  Contraindication to any drug contained in the R-GEMOX chemotherapy regimen

          -  Any serious active disease or co-morbid medical condition (according to the
             investigator's decision),

          -  Poor renal function (creatinine level &gt; 150micromol/l), poor hepatic function (total
             bilirubin level &gt; 30mmol/l, transaminases &gt; 2.5 maximum normal level) unless these
             abnormalities are related to the lymphoma

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.5 G/l or platelets &lt; 100 G/l,
             unless related to bone marrow infiltration

          -  Any history of cancer during the last 5 years, with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study

          -  Any radiotherapy during the four weeks before inclusion

          -  Pregnant or lactating woman

          -  Adult patient unable to give informed consent because of intellectual impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, Créteil, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital henri Mondor, Créteil, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique - CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Sang - CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service D'Hématologie Adulte - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.</citation>
    <PMID>11807147</PMID>
  </reference>
  <reference>
    <citation>Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, Norman A, Gill K, Howard A, Catovsky D. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol. 2001 Dec;115(4):786-92.</citation>
    <PMID>11843810</PMID>
  </reference>
  <reference>
    <citation>Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, Frénoy N, Emile JF, Debuire B, Guettier C, Farrokhi P, Boulefdaoui B, Norol F, Parquet N, Ulusakarya A, Jasmin C. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol. 2001 Oct;12(10):1439-43.</citation>
    <PMID>11762817</PMID>
  </reference>
  <reference>
    <citation>Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44(2):117-23.</citation>
    <PMID>10412945</PMID>
  </reference>
  <reference>
    <citation>Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, Johnson SA. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol. 2000 May;11(5):595-7.</citation>
    <PMID>10907954</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell lymphoma</keyword>
  <keyword>Salvage Therapy</keyword>
  <keyword>rituximab</keyword>
  <keyword>oxaliplatine</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

